Amplia Therapeutics and the Australia New Zealand Gynaecological Oncology Group (ANZGOG) have partnered to conduct a clinical trial testing narmafotinib combined with standard chemotherapy in ovarian cancer patients who do not respond to platinum-based treatment. The PRROSE trial will enroll 15-20 patients with high-grade serous ovarian cancer to evaluate safety and potential improvement in surgical outcomes. This study addresses a critical need as about 20% of ovarian cancer patients fail initial chemotherapy, limiting surgery options and worsening prognosis. Biomarker analysis will also explore narmafotinib's mechanism to support future treatment development.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
UnitedHealth Group reported second-quarter earnings that surpassed expectations, driven by better management of high medical costs and AI investments to streamline operations. The company raised its 2026 adjusted earnings forecast to $19.50-$20 per s...
Meta Platforms has been upgraded to a buy rating due to its new cloud business, which is expected to stabilize cash flow and improve profitability. Despite heavy capital expenditures, Meta maintains strong free cash flow margins and operational effic...
Bitcoin Treasury Capital, a Stockholm-based firm, has received approval to issue 195,078 Class A preferred shares on the Spotlight Stock Market, starting July 20, 2026. These shares, priced at SEK 120 each, offer a 10% annual dividend backed entirely...
Bitcoin price recently hit a strong resistance level at $65,600 but failed to break through, signaling a possible reversal. Short-term momentum is weakening, suggesting the price may decline unless a sudden surge occurs. Key support levels include th...
